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Received August 24, 2010; accepted December 20, 2010AbstractBackground: The optimal treatment of base of tongue squamous cell carcinoma (BOTSCC) remains controversial. To optimize treatment
planning, this study analyzed the outcomes of patients with BOTSCC treated in Taipei Veterans General Hospital.
Methods: Retrospective chart reviews were performed for 107 patients with BOTSCC from January 1990 to December 2004, and 85 patients
were included, with a mean follow-up interval of 38 months. Patients were divided into surgical and radiotherapy/chemoradiation therapy (RT/
CRT) groups. Potentially significant variables for survival were analyzed.
Results: The 3-year overall survival (OS) and disease-free survival rates were 40% and 37.1%, respectively. No significant differences in the
patient and disease characteristics between the surgical (n ¼ 39) and RT/CRT groups (n ¼ 46) were found. Advanced overall stage ( p ¼ 0.034),
cervical lymph node metastasis ( p ¼ 0.007), and regional recurrence ( p ¼ 0.024) were poor prognostic factors for OS. In early-stage disease
(Stages I and II), the 3-year OS was higher in the surgical group (68.6%) than in the RT/CRT group (37.5%), but the significance was only
borderline ( p ¼ 0.071). There was no significant difference in the 3-year OS between the patients in the surgical and CT/CRT groups with
advanced-stage disease. In the surgical group, lymphovascular permeation ( p ¼ 0.015) and soft-tissue involvement ( p ¼ 0.01), determined by
pathologic examination, were poor prognostic factors for OS. Recurrence occurred in 35 patients (41.2%), with no significant difference in local,
regional, or distant control between the surgical and RT/CRT groups.
Conclusion: These findings emphasize the importance of neck disease control in the treatment of BOTSCC. Although currently, RT/CRT is used
more frequently, surgery may still have a role in the treatment of early-stage disease. Both surgery with adjuvant therapy and RT/CRT produced
equivalent survival rates in the treatment of advanced-stage disease, but the recurrence rate was unsatisfactory. A more effective treatment
modality with less early and late toxicity is needed.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Although research has reported good results of oropha-
ryngeal squamous cell carcinoma treated by chemoradiation
therapy (CRT),1,2 the optimal treatment of base of tongue* Corresponding author. Dr. Tung-Lung Tsai, Department of Otorhinolar-
yngologydHead and Neck Surgery, Taipei Veterans General Hospital, 201,
Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC.
E-mail address: tltsai@vghtpe.gov.tw (T.-L. Tsai).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.03.007squamous cell carcinoma (BOTSCC) remains controversial.2,3
In BOTSCC, reports indicate that the treatment response is
significantly worse than that for other oropharyngeal subsites.2
Furthermore, evidence from a population-based study of the
United States National Cancer Data Base, which included
16,188 cases of BOTSCC, did not support the superiority of
nonsurgical treatment because it failed to provide favorable
survival outcome.3 Patients with favorable T1 and T2 lesions
can be treated with surgery or radiotherapy (RT) alone. Radicalhinese Medical Association. All rights reserved.
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in patients with advanced BOTSCC because of higher rates of
locoregional control, but this often results in dysfunction of
swallowing and speech.4 Nonsurgical treatments with CRT
have shown equivalent oncologic results. However, debates
about whether surgery with or without adjuvant therapy
produces better oncologic results than nonsurgical protocols,
particularly for advanced tumors, are ongoing.
Poor control of disease in patients with BOTSCC has been
attributed to the advanced stage of disease when diagnosed,
which results from many factors including tumor behavior,
anatomic factors, and the patient’s personality and socioeco-
nomic status. The purpose of this study was to analyze the
clinical presentation, treatment response, failure patterns, and
rates of survival among patients with BOTSCC treated in
Taipei Veterans General Hospital (VGHTPE) to optimize the
planning and choice of treatment modality.
2. Methods
This study was approved by the Institutional Review Board
of VGHTPE. From January 1990 to December 2004, 107
patients with BOTSCC were seen at the Department of
OtorhinolaryngologydHead and Neck Surgery of VGHTPE.Table 1
Patients’ characteristics
Characteristics All patients
(n ¼ 85)
Mean follow-up (mo) 38.0 (1.3e180.5)
Sex
Men 77 (90.6)
Women 8 (9.4)
Age (yr) 57 (28e84)
Clinical stage
Early (I, II) 18
Late (III, IV) 67
T stage
T1 10 (11.8)
T2 35 (41.2)
T3 24 (28.2)
T4a 11 (12.9)
T4b 5 (5.9)
N stage
N0 25 (29.4)
N1 13 (15.3)
N2a 4 (4.7)
N2b 22 (25.9)
N2c 13 (15.3)
N3 8 (9.4)
Overall stage
I 5 (5.9)
II 13 (15.3)
III 13 (15.3)
IVA 41 (48.2)
IVB 13 (15.3)
Data are presented as number  standard deviation with percentage or range in pTheir medical records were reviewed retrospectively. All the
diagnoses were proved by biopsy and pathologic examination.
The tumors were re-staged retrospectively based on the 2002
criteria of the American Joint Committee on Cancer classifi-
cation.5 Patients who received any type of curative resection at
the primary site with or without neck dissection (ND) as initial
treatment were defined as the surgical group. The RT/CRT
group was composed of patients who were treated with RT or
CRT as definitive therapy. Patients who underwent salvage
surgery performed after the completion of CRT or RTwere not
included in the surgical group. The exclusion criteria for
analysis were the presence of other underlying malignancies,
previous treatment of BOTSCC, and distant metastasis (DM)
at the time of diagnosis. Of the 107 patients identified, 4
patients had metastatic disease at the time of diagnosis and 18
patients did not receive curative treatment at VGHTPE. Thus,
85 patients were included in this study.2.1. Statistical analysisOverall survival (OS) was defined as the interval between
the initial date of treatment and the date of death. The interval
between the initial date of treatment and the date of the last
consultation was defined as censored times. For theSurgery
(n ¼ 39)
Nonsurgery
(n ¼ 46)
46.8 (2.37e180.5) 29.5 (1.3e153.3)
34 (87.2) 43 (93.5)
5 (12.5) 3 (6.5)
57.6  11.7 (30e83) 56.5  13.2 (28e84)
10 (25.6) 8 (17.4)
29 (74.4) 38 (82.6)
8 (20.5) 2 (4.3)
13 (33.3) 22 (47.8)
11 (28.2) 13 (28.3)
5 (12.8) 6 (13)
2 (5.1) 3 (6.5)
12 (30.8) 13 (28.3)
5 (12.8) 8 (17.4)
2 (5.1) 2 (4.3)
10 (25.6) 12 (26.1)
7 (17.9) 6 (13)
3 (7.7) 5 (10.9)
4 (10.3) 1 (2.2)
6 (15.4) 6 (15.2)
5 (12.8) 7 (17.4)
20 (51.3) 21 (45.7)
4 (10.3) 9 (19.6)
arentheses.
Table 2
Appearance of tumors and the sites of tumor extension
n (%)
Tumor appearance
Exophytic 45 (52.9)
Endophytic 15 (17.6)
Ulcerative 25 (29.4)
Site of tumor extension
Vallecula 23 (27.1)
Midline cross 21 (24.7)
Oral tongue 15 (17.6)
Ipsilateral tonsil 13 (15.3)
Ipsilateral pharyngeal wall 12 (14.1)
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deaths and deaths because of second primary tumors, as well
as patients alive without recurrence, were regarded as censored
observations. SPSS version 15.0 (SPSS Inc., Chicago, IL,
USA) was used for data analyses. OS and DFS were generated
by the Kaplan-Meier method, and statistically significant
differences between survival rates were determined by log-
rank test. Multivariate analysis was conducted by the Cox
regression method. Categorical and continuous data were
evaluated by the c2 method and t test, respectively. Probability
values of less than 0.05 were considered statistically
significant.Floor of mouth 9 (10.6)
Epiglottis 9 (10.6)3. Results
Arytenoid-epiglottic fold 7 (8.2)
Pre-epiglottic space 5 (5.9)
Pyriform sinus 4 (4.7)3.1. Clinical data
Skull base 1 (1.2)
Soft palate 1 (1.2)
Gingiva 1 (1.2)
Retromolar trigone 1 (1.2)
Mandible 1 (1.2)
Hyoid bone 1 (1.2)
Neck soft tissue 1 (1.2)Table 1 shows the details of clinical tumor, nodes, and
metastases stages and treatment methods. Of the known risk
factors, 72.9% and 60.5% of the patients used tobacco and
alcohol, respectively. Fig. 1 includes the initial presenting
symptoms. The most common symptoms were tongue pain
(31.7%), neck mass (28.2%), and odynophagia (23.5%). The
mean symptomatic period before seeking care was 4 months.
Midline lesions were present in 14.3% of patients. Table 2
summarizes tumor appearances and the sites of tumor exten-
sions. Only 18 patients (21.2%) had diagnoses of early-stage
disease, and 60 patients (70.6%) had cervical lymph node
(LN) metastasis when their conditions were diagnosed. The
patient and disease characteristics were not significantly
different between the surgical (n ¼ 39) and RT/CRT groups
(n ¼ 46), as indicated in Table 1.
In the surgical group, larger surgical defects were recon-
structed with pectoralis major myocutaneous flaps in 12
patients and a rotational tongue flap in 1 patient. ND was
performed in 32 patients (82.1%), including ipsilateral
dissection in 23 (71.9%) and bilateral dissection in 9 patients
(23.1%). Seven NDs were elective for patients with clinical N0
disease.Fig. 1. Distribution of initial presenting symptoms. FBS ¼ foreign body
sensation.The grades of tumors in the final pathology reports were
well differentiated in 6 (15.4%), moderately differentiated in
19 (48.7%), and poorly differentiated in 5 (12.8%). For the 33
tumors with available surgical margin reports, 27 (69.3%) had
negative margins and 6 (15.4%) had positive margins. Cervical
LN metastasis was confirmed in 26 patients (66.6%), and
extracapsular spreading of tumor cells was found in four
patients (10.2%). The mean number of neck LN metastases
was 4.2 (range, 1e10). Occult neck metastasis was confirmed
in 1 of 7 (14.3%) patients with clinical N0 disease after ND.
According to the final pathology report, the overall stage was
downgraded in three patients (7.7%), from Stage IV to III in
one patient and from Stage II to I in two patients; and it was
upgraded in two patients (5.1%), from Stage I to II in one
patient and from Stage II to III in one patient.
Twenty-nine patients (74.4%) received postoperative RT,
and three patients (7.7%) received postoperative CRT. The
indications for postoperative adjuvant therapy were T4 tumor
determined by pathology, advanced N2 or N3 neck disease,
and unfavorable pathologic factors such as perineural invasion,
lymphovascular permeation, tumor emboli, extracapsular
spreading, and positive surgical margins. All patients who
underwent adjuvant therapy received continuous-course
external-beam RT to the primary cancer with once-daily
fractionation. The mean total dose was 6,180 cGy, with a mean
fraction of 31.
In the RT/CRT group, 16 patients (18.8%) received RT
alone and 30 patients (35.3%) received primary CRT with the
aim of preserving the tongue and its function. The intended
dose of irradiation to the primary site and gross lymphade-
nopathy (1 cm) was 7,000 cGy, whereas it was 5,000 cGy to
the N0 neck. The mean total dose was 6,910 cGy to the
primary site, with a mean fraction of 37 (range, 18e61). The
Table 3
Three-year overall survival rates (calculated by Kaplan-Meier method)
according to the T, N, and overall stages
N0 I II III IVA IVB
T stage (%) 70 34.3 45.8 25
N stage (%) 56 38.5 35.9 12.5
Overall stage (%) 83.3 50 46.2 39 7.7
1.0
0.8
0.6
0.4
Censor
Soft tissue 
involvement (+)
Soft tissue 
involvement (-)
n=20
p=0.01
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days). Since 2000, CRT has been the most frequently used
treatment of oropharyngeal cancer at VGHTPE. The
percentage of patients treated with RT/CRT increased from
46% in the 1990s to 65% after January 2000, and this increase
was significant ( p ¼ 0.01).0.2
n=53.2. Oncologic results60483624120
0.0
Fig. 2. Kaplan-Meier projected overall survival in the surgical groups with/
without soft-tissue involvement. All five patients in the soft-tissue involvement
(þ) group died; 10 of 20 patients in the soft-tissue involvement () group
died.With a mean follow-up of 38 months (range, 1.3e180.5
months), 51 of 85 patients died, 20 patients from the surgical
group and 31 patients from the RT/CRT groups. The 3-year OS
and DFS were 40% and 37.1%, respectively. The 3-year local
and regional control rates were 77.1% and 81.8%, respectively.
Table 3 summarizes the 3-year survival rates according to the
T, N, and overall stages. As shown in Table 4, the prognostic
factors that affected OS unfavorably were advanced overall
clinical stage ( p ¼ 0.034), cervical nodal involvement
( p¼ 0.007), and regional recurrence ( p¼ 0.024). Multivariate
analysis found no specific independent prognostic factor.
In the surgical group, pathology results indicating soft-
tissue involvement (tumor extension into adjacent fat, muscle,
salivary gland, or skin) and lymphovascular permeation were
significant poor prognostic factors for 3-year OS (Figs. 2Table 4
Analysis of the prognostic factors influencing 3-year OS
Characteristics n Univariate analysis
3-yr OS 95% CI
Sex
Male 77 41.6 30.6e52.6
Female 8 25 0e55
Age
&60 yr 47 46.8 32.5e61.1
＞60 yr 38 31.6 16.9e46.3
Clinical stage
Early (I, II) 18 61.1 38.5e83.6
Late (III, IV) 67 34.3 22.9e45.7
T stage
T1, 2 45 42.2 27.7e56.7
T3, 4 40 37.5 22.4e52.6
N stage
N() 25 56 55.3e117.1
N(þ) 50 33.3 26.5e47.3
Local recurrence
Yes 13 18.8 13.6e48.6
No 72 44.9 39.2e70.5
Regional recurrence
Yes 13 8.3 6.2e31.7
No 72 45.2 41.1e80
CI ¼ confidence interval; NS ¼ non-significant; OS ¼ overall survival; RR ¼ riskand 3). Among patients with early-stage (Stages I and II)
disease, there was a trend toward a survival benefit with
surgery compared with RT/CRT; the OS rates were 68.6% and
37.5%, respectively, with borderline significance ( p ¼ 0.071).
A total of 35 patients suffered from recurrence/DM
(Table 5). Six patients (7.1%) had metastasis to the lung,
which was the most common site for DM. The mean time toMultivariate analysis
p RR 95% CI p
NS
NS
0.034 NS
1.69 0.5e5.78
NS
0.007 NS
1.16 0.41e3.31
NS
0.024 NS
1.69 0.85e3.37
ratio.
60483624120
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0.2
0.0
Censor
Lymphovascular 
permeation (+)
Lymphovascular 
permeation (-)
n=21
n=3
p=0.015
Fig. 3. Kaplan-Meier projected overall survival in the surgical group with/
without lymphovascular permeation. All three patients in the lymphovascular
permeation (þ) group died; 11 of 21 patients in the lymphovascular perme-
ation () group died.
Table 6
Salvage treatments for recurrence/distant metastasis
Salvage treatment n
Surgery alone 6
Surgery followed by radiation 3
Chemoradiation 2
Radiation alone 4
Chemotherapy alone 11
Total 26
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(range, 3.2e31.3 months), and 91.4% of recurrences occurred
within 2 years after initial treatment. Recurrence occurred less
frequently in N() disease (28%) than in N(þ) disease
(46.7%). There was no significant difference in local/regional/
distant control when the surgical and RT/CRT groups were
compared. In the surgical group, only soft-tissue involvement
was a significant negative pathologic prognostic factor for the
rate of regional control ( p < 0.001).
Twenty-six patients (74.3%) with recurrence/DM received
salvage treatments (Table 6). However, the rate of successful
salvage was very poor; and the mean survival after recurrence
was 13.3 months (range, 0.2e92 months). There were no
significant prognostic factors affecting the rate of survival
after salvage among patients with recurrence. Among patients
with early-stage disease who had surgical intervention
(n ¼ 10), a midline location of the primary tumor (n ¼ 2) was
associated with a higher recurrence rate compared with tumors
with laterality (n ¼ 8); the recurrence rates were 50% and
12.5%, respectively. A second primary malignancy occurred inTable 5
Treatment failure patterns (n ¼ 35)
Failure pattern Number of
patients
Surg
thera
Local recurrence 13 6
Locoregional recurrence 1 1
Neck recurrence 12 4
Distant metastasis and local recurrence 2 1
Distant metastasis and locoregional control 7 4eight patients (9.4%), and the oral cavity (n ¼ 2) was the most
common site.
4. Discussion
Because a large portion of the whole tongue is occupied by
the BOT, tumors can infiltrate deeply before significant
symptoms occur. Clinically, a tumor in this area is difficult to
detect in the early stages. Gourin et al.6 reported that up to
91% of their patients presented with T3/4 disease. In our
study, 48.2% presented with T3/4 stage, and 71.6% presented
with LN metastasis at the time of diagnosis. In this study,
tongue pain was the most common symptom of BOTSCC. The
relatively asymptomatic nature of BOTSCC at an early stage
and its high cervical LN metastasis rate make late-stage
disease common at the time of diagnosis, which results in
a poor survival rate.
In the early stage (Stages I and II) of BOTSCC, survival
rates of patients treated with RT, surgery, or combined
modalities have been reported to be between 50% and 70%.7
In our patients with early-stage disease, the 3-year OS was
61.1%, and the surgical group had a slightly superior survival
rate compared with RT/CRT treatment. This finding is
compatible with the result of the United States National
Cancer Data Base analysis, which revealed that patients
treated by surgery with or without RT have favorable survival
in early-stage disease.3 The possible reason for our finding
may be that the survival after salvage for recurrence is rela-
tively higher in the surgical group (50%) as opposed to the
nonsurgery group (0%) in early-stage patients. After high-dose
radiotherapy as primary treatment in the nonsurgery group,
most recurrent oropharyngeal cancer patients were poor
candidates for salvage treatment.8 Higher local recurrence
rates occurred in midline lesions as opposed to those with
laterality among the surgical group. Difficulty in exposure of
midline lesions by traditional surgical approaches may be theery and adjuvant
py (n ¼ 16)
Chemoradiation therapy
(n ¼ 14)
Radiotherapy
alone (n ¼ 5)
4 3
0 0
6 2
1 0
3 0
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suitable for such lesions.
The treatment of advanced-stage (Stages III and IV)
BOTSCC often requires a multimodal strategy for adequate
disease control, such as surgery plus postoperative RT or
combined CRT. Some authors have suggested primary RT,9,10
whereas others promote surgery with adjuvant therapy.3,11 If
surgery was the primary treatment, data support the combi-
nation of postoperative RT for patients with advanced
disease.3,12,13 For advanced-staged BOTSCC treated by
surgery and postoperative RT, the 5-year survival rate was
approximately 60%.12e14
In head and neck cancers, locoregional control of
advanced-stage disease was improved through the use of more
aggressive courses of radiation or the addition of chemo-
therapy.15 However, the late toxic effects of CRT are no less
severe than the complications of surgery. A high rate of
dysphagia, aspiration, and long-term gastric tube dependence
was reported among patients with BOTSCC treated by
CRT.16e18 In advanced BOTSCC, organ preservation by
nonsurgical treatment does not always promise the preserva-
tion of function and improvement in quality of life.
From our study, advanced overall stage, cervical LN
metastasis, and regional recurrence were prognostic factors
that indicated poor OS in univariate analysis. The 3-year OS
rate decreased from 56% to 33.3% if neck metastasis occurred.
Unfavorable histopathologic features including positive
surgical margin, perineural invasion, lymphovascular perme-
ation, tumor emboli, node level, and number, size, and pres-
ence of extracapsular extension have been shown to be
associated with increased risk of recurrence in head and neck
cancers.19 In the surgical group, lymphovascular permeation
and soft-tissue involvement were significant poor prognostic
factors for OS. This study found that neck recurrence was
almost twice as likely to occur in histopathologically deter-
mined N(þ) necks compared with N() necks (46.7% vs.
28%, respectively), and Leemans et al reported a similar
result.20 These findings highlight the importance of disease
control in neck for the treatment of BOTSCC. Postoperative
adjuvant CRTwas highly recommended to reduce the negative
effect of these risk factors in BOTSCC.
In conclusion, BOTSCC is an aggressive disease that is
often diagnosed at a late stage and is characterized by poor
survival rates despite improvements in current standard
therapy. Advanced overall stage, cervical LN metastasis, and
regional recurrence were identified as poor prognostic factors
in our patients with BOTSCC. The analysis of surgical group
suggested that neck control is very important for OS. Although
RT/CRT treatment modalities are used more frequently,
surgery may still have a role in the treatment of patients with
BOTSCC at an early stage because of better salvage survival
rate after recurrence. A more effective treatment modality with
less early and late toxicity is needed for the treatment of
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